Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease.

BACKGROUND Epidemiological studies consistently demonstrate synergy between herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1). Higher HIV-1 loads are observed in coinfected individuals, and conversely, HIV-1 is associated with more-severe herpetic disease. A small animal model of coinfection would facilitate identification of the biological mechanisms underlying this synergy and provide the opportunity to evaluate interventions. METHODS Mice transgenic for HIV-1 provirus and human cyclin T1 under the control of a CD4 promoter (JR-CSF/hu-cycT1) were intravaginally infected with HSV-2 and evaluated for disease progression, HIV shedding, and mucosal immune responses. RESULTS HSV-2 infection resulted in higher vaginal HIV loads and genital tissue expression of HIV RNA, compared with HSV-uninfected JR-CSF/hu-cycT1 mice. There was an increase in genital tract inflammatory cells, cytokines, chemokines, and interferons in response to HSV-2, although the kinetics of the response were delayed in HIV-transgenic, compared with control mice. Moreover, the JR-CSF/hu-cycT1 mice exhibited earlier and more-severe neurological disease. The latter was associated with downregulation of secretory leukocyte protease inhibitor expression in neuronal tissue, a molecule with antiinflammatory, antiviral, and neuroprotective properties. CONCLUSIONS JR-CSF/hu-cycT1 mice provide a valuable model to study HIV/HSV-2 coinfection and identify potential mechanisms by which HSV-2 facilitates HIV-1 transmission and HIV modulates HSV-2-mediated disease.

[1]  Jianwei Hou,et al.  Secretory Leukocyte Protease Inhibitor Reverses Inhibition by CNS Myelin, Promotes Regeneration in the Optic Nerve, and Suppresses Expression of the Transforming Growth Factor-β Signaling Protein Smad2 , 2013, The Journal of Neuroscience.

[2]  T. Miura,et al.  Imbalanced production of cytokines by T cells associates with the activation/exhaustion status of memory T cells in chronic HIV type 1 infection. , 2012, AIDS research and human retroviruses.

[3]  Sunhee C. Lee,et al.  Regulation of Progranulin Expression in Human Microglia and Proteolysis of Progranulin by Matrix Metalloproteinase-12 (MMP-12) , 2012, PloS one.

[4]  R. Kaul,et al.  Characterization of a Human Cervical CD4+ T Cell Subset Coexpressing Multiple Markers of HIV Susceptibility , 2011, The Journal of Immunology.

[5]  G. Doncel,et al.  Bridging the Gap between Preclinical and Clinical Microbicide Trials: Blind Evaluation of Candidate Gels in Murine Models of Efficacy and Safety , 2011, PloS one.

[6]  R. Kaiser,et al.  Prevalence of Herpes Simplex Virus Type 2 Infection, Human Immunodeficiency Virus/Herpes Simplex Virus Type 2 Coinfection, and Associated Risk Factors in a National, Population-Based Survey in Kenya , 2011, Sexually transmitted diseases.

[7]  Shalini Sharma,et al.  Role of IL-17 and Th17 Cells in Herpes Simplex Virus-Induced Corneal Immunopathology , 2011, Journal of Immunology.

[8]  A. Wald,et al.  Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor , 2011, Infectious diseases in obstetrics and gynecology.

[9]  D. Bernstein,et al.  Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy. , 2010, Antiviral research.

[10]  A. Gettie,et al.  A Macaque Model to Study Vaginal HSV-2/Immunodeficiency Virus Co-Infection and the Impact of HSV-2 on Microbicide Efficacy , 2009, PloS one.

[11]  A. Finnegan,et al.  HSV type 2 infection increases HIV DNA detection in vaginal tissue of mice expressing human CD4 and CCR5. , 2009, AIDS research and human retroviruses.

[12]  Sarah S. Wilson,et al.  Susceptibility to Genital Herpes as a Biomarker Predictive of Increased HIV Risk: Expansion of a Murine Model of Microbicide Safety , 2009, Antiviral therapy.

[13]  D. Douek,et al.  Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. , 2008, Blood.

[14]  Aimin Li,et al.  Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. , 2008, Fertility and sterility.

[15]  Sarah S. Wilson,et al.  Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism , 2008, Journal of Virology.

[16]  Scott Rose,et al.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[17]  J. Berger,et al.  Neurological complications of herpes simplex virus type 2 infection. , 2008, Archives of neurology.

[18]  D. Littman,et al.  Relief of Preintegration Inhibition and Characterization of Additional Blocks for HIV Replication in Primary Mouse T Cells , 2008, PloS one.

[19]  Louise Knight,et al.  Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. , 2008, The New England journal of medicine.

[20]  R. Kaul,et al.  Sexual Risk Factors for HIV Infection in Early and Advanced HIV Epidemics in Sub-Saharan Africa: Systematic Overview of 68 Epidemiological Studies , 2007, PloS one.

[21]  A. Ouedraogo,et al.  Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies , 2007, Sexually Transmitted Infections.

[22]  L. Corey Synergistic copathogens--HIV-1 and HSV-2. , 2007, The New England journal of medicine.

[23]  Vincent Foulongne,et al.  Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. , 2007, The New England journal of medicine.

[24]  Mardge H. Cohen,et al.  Herpes simplex virus infection in women in the WIHS: Epidemiology and effect of antiretroviral therapy on clinical manifestations , 2006, AIDS.

[25]  L. Santambrogio,et al.  CD4-Specific Transgenic Expression of Human Cyclin T1 Markedly Increases Human Immunodeficiency Virus Type 1 (HIV-1) Production by CD4+ T Lymphocytes and Myeloid Cells in Mice Transgenic for a Provirus Encoding a Monocyte-Tropic HIV-1 Isolate , 2006, Journal of Virology.

[26]  S. Wallenstein,et al.  Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. , 2005, The Journal of infectious diseases.

[27]  C. Quereda,et al.  Sacral myeloradiculitis complicating genital herpes in a HIV-infected patient , 2005, International journal of STD & AIDS.

[28]  F. Barone,et al.  Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. , 2003, Molecular pharmacology.

[29]  A. Wald,et al.  How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? , 2003, The Journal of infectious diseases.

[30]  R. Hayes,et al.  Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. , 2000, The Journal of infectious diseases.

[31]  D. Marcellino,et al.  Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. , 2000, Virology.

[32]  J. Orenstein,et al.  Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV‐1 , 1997 .

[33]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[34]  J. Justement,et al.  Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. , 1987, Science.

[35]  A. Hays,et al.  A new compllication of AIDS , 1985, Neurology.

[36]  K. Sango,et al.  Novel mouse models for understanding HIV-1 pathogenesis. , 2009, Methods in molecular biology.

[37]  A. Hays,et al.  A new complication of AIDS: thoracic myelitis caused by herpes simplex virus. , 1985, Neurology.